Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

This PQI in Action is a follow up to the Siltuximab in Patients with Idiopathic Multicentric Castleman Disease and explores how the medically integrated teams at University of Michigan Health-Sparrow Herbert-Herman Cancer Center, Texas Oncology, and University of North Carolina (UNC) Health collaborate and utilize the information found in the PQI as part of their daily practice. This PQI in Action focuses on the use of siltuximab in patients with idiopathic multicentric Castleman Disease.